Calcitriol and postmenopausal osteoporosis.
Sambrook
P
P
Garvan Institute of Medical Research, St Vincent's Hospital, Sydney.
D045930:Anabolic Agents / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D002117:Calcitriol / Q000009:adverse effects / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D012969:Sodium Fluoride / Q000627:therapeutic use
D045930:Anabolic Agents; D002136:Calcium, Dietary; D012969:Sodium Fluoride; D002117:Calcitriol; D012968:Etidronic Acid